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Numerous EU documents praise the excellence of EU research without empirical 
evidence and against academic studies. We investigated research performance in 
two fields of high socioeconomic importance, advanced technology and basic 
medical research, in two sets of European countries, Germany, France, Italy, and 
Spain (GFIS), and the UK, the Netherlands, and Switzerland (UKNCH). Despite 
historical and geographical proximity, research performance in GFIS is much 
lower than in UKNCH, and well below the world average. Funding from the 
European Research Council (ERC) greatly improves performance both in GFIS 
and UKNCH, but ERC-GFIS publications are less cited than ERC-UKNCH 
publications. We conclude that research performance in GFIS and in other EU 
countries is intrinsically low even when it is generously funded. The 
technological and economic future of the EU depends on improving research, 
which requires structural changes in research policy within the EU, and in most 
EU countries. 
 
1. Introduction 
 
Compelling evidence from academic studies demonstrates the weakness of European research 
(Albarrán et al. 2010; Bauwens et al. 2011; Bonaccorsi 2007; Bonaccorsi et al. 2017a; Dosi et al. 2006; 
Herranz and Ruiz-Castillo 2013; Rodriguez-Navarro and Narin 2018; Rodríguez-Navarro and Brito 
2018b), especially in fields that are at the forefront of technological knowledge (Bonaccorsi 2007; 
Rodriguez-Navarro and Narin 2018; Sachwald 2015). This situation has never been addressed by the 
European Commission (EC), which on the contrary has developed research policies assuming that 
European research is excellent. For many years, EU research policy was based around the “European 
paradox,” which proclaims strong research and weak innovation in the EU. Recently, references to this 
paradox have disappeared from EC documents, but the notion is as present as it was when it was defined 
24 years ago (European Commission 1995). 
A report from an independent High Level Group appointed by the EC (European Commission 2016) 
begins by describing EU research as in the European paradox: “When looking ahead to the future of 
Europe in a globalising world, the contrast is striking between Europe’s comparative advantage in 
producing knowledge and its comparative disadvantage in turning that knowledge into innovation and 
growth;” the next sentence is a motto “Europe is a global scientific powerhouse” (European Commission 
2017b, p. 7). Regretfully, this report is the foundation for the preparation of the Horizon Europe research 
program for the 2021–2027 period. This program is based on the notion that “Europe is a world leader in 
science” (European Commission 2018a, p. 11); and that “In a swiftly changing world, Europe’s success 
increasingly depends on its ability to transform excellent scientific results into innovation that have a real 
beneficial impact” (European Commission 2018b, p. 1). Consistent with these statements, EC optimism is 
also demonstrated in the press releases; for example: “A new programme – Horizon Europe – will build on 
the achievements and success of the previous research and innovation programme (Horizon 2020) and 
keep the EU at the forefront of global research and innovation” (http://europa.eu/rapid/press-release_IP-18-
4041_en.htm, accessed on 7 March, 2019). Many examples of this type demonstrate that the EC is not 
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aware that research in the EU is weak. If the EU research policy is based on these convictions, it is likely 
that the EU research weakness will never be corrected. 
It seems evident that the first step in an efficient research policy is that the EC recognizes and addresses 
the weaknesses of EU research, especially in technology. Only this would make it possible for the EU to 
return to past research successes. To achieve this, it is necessary to widen the description and 
characterization of this weakness, expressing the results in terms that are clear to a wide audience. 
This purpose, however, is more complex than it would be in a developing country, where simple 
indicators can be used. The EU is a powerful economy, it was a world scientific leader not so long ago, it 
still produces an enormous amount of scientific research, and it has competitive industries that are able to 
maintain a high level of incremental innovations. The current EU research weakness cannot, therefore, be 
correctly described using simple indicators that are unable to detect complex problems. For example, the 
statements: “The EU is a global research powerhouse responsible for one-fifth of all R&D investments 
worldwide” and “In terms of overall scientific production, Europe is in the lead, ahead of the United States 
and China” (European Commission 2018c, p. 78 and 154) are true, but they are irrelevant truths. 
Investments and overall scientific production say nothing about discoveries and knowledge advancements, 
which are the driving force of technological advances and the roots of radical innovations. These 
achievements define the real research powerhouses and they are where EU research fails. 
 
2. Aims of this study 
 
This study aims to further characterize the weakness of the EU research performance described above 
and investigate its causes. For this purpose it focuses on two research fields of high socioeconomic 
importance: advanced technology and basic medical research, and compares the performance of a small 
number of countries within the European Research Area (ERA) with excellent research indicators with that 
of countries that represent the generally low performance of most EU countries (Brito and Rodríguez-
Navarro 2018b; Rodríguez-Navarro and Brito 2018b). As a second tool, this study focuses on the research 
funded by the European Research Council (ERC), as a means to single out elite and generously funded 
research in high and low performance countries. 
 
3. The decline of research in some but not in all European countries 
 
The most remarkable characteristic of research in Europe is that at the beginning of the twentieth 
century, Europe (excluding Russia) was not only a global scientific powerhouse (Davies 1997), but the 
only global scientific powerhouse attending to the number of Nobel prizes (Heinze et al. 2019). In the first 
14 years of Nobel Prize awards before World War I (1901–1914), out of a total of 49 Nobel laureates in 
natural sciences, 46 were Europeans. Comparable figures over a recent 14-year period (2001–2014) are 
more difficult to tally because of the large number of shared prizes, but it is remarkable that there was not a 
single year without awards to USA researchers, which was not the case for Europe. This decline mainly 
affected Germany and France, however, less so the UK (Gros 2018); see also Bauwens et al. 2011). Thus, 
the most important cause of the decline in European research has been the decline of German and French 
research, while some northern EU countries have not been affected—or to a lesser extent—by the decline. 
Consistent with their scarcity in Nobel awards, the current research performance of Germany and 
France at the forefront of technological and biological research is disappointing, and well below the global 
average. This low performance does not occur in all EU countries; in fact, the UK and the Netherlands (in 
the EU) and Switzerland (in the ERA) maintain highly competitive research (Brito and Rodríguez-Navarro 
2018b; Rodríguez-Navarro and Brito 2018b). 
These large differences across countries can lead to an incomplete perception of the weakness of EU 
research if they are not taken into consideration; however, most of the studies that have so far examined 
the weakness of EU research have considered the EU as a whole (e.g., Albarrán et al. 2010; Dosi et al. 
2006; Herranz and Ruiz-Castillo 2013; Rodriguez-Navarro and Narin 2018), and this does not help in 
finding solutions to a problem that needs to be addressed at the country level. According to population, 
size, and degree of socioeconomic development, the set of countries with the greatest responsibility for 
weak research performance in the EU is Germany, France, Italy, and Spain (henceforth GFIS; see Table 2 
in Bauwens et al. 2011; Tables 1 and 3 in Brito and Rodríguez-Navarro 2018b; and Table 5 in Rodríguez-
Navarro and Brito 2018b). These countries represent approximately 50% of the EU population and 55% of 
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its GNP, and, therefore, the study of these four countries, rather than the study of the whole EU, should 
give a more clear diagnostic of the difficulties of EU research in competing at the forefront of knowledge. 
 
4. Research performance can be robustly measured 
 
Discrepancies between different types of research assessment have their roots in the difficulties of this 
type of assessment. These difficulties explain why, for over 20 years, EU research policy has been based 
on the wrong diagnoses of the performance of the EU research system (Dosi et al. 2006). Bibliometric 
indicators based on counting publications and citations have been used for a long time (Godin 2003, 2006). 
However, if the purpose is to estimate contribution to the advancement of knowledge then most of these 
indicators give misleading information. This is because only a very low proportion of the total number of 
publications reports important scientific breakthroughs. This can be explained by distinguishing between 
“normal” and “revolutionary” science (Kuhn 1970), and also by taking into consideration that so far “the 
benefits of scientific discoveries have been heavy-tailed” (Press 2013, p. 822). This implies that the 
evaluation of the publications in this tail is what really counts in research assessment. However, because 
the identification and evaluation of these publications is difficult, most indicators “are largely based on 
what can easily be counted rather on what really counts” (Abramo and D'Angelo 2014, p. 1130), which has 
been also expressed as “not everything that can be counted counts, and not everything that counts can be 
counted” (Cameron 1963, p. 13). 
Counting the number of Nobel prizes has occasionally been used as a reliable indicator of research 
success (e.g., Braun et al. 2003; Charlton 2007b, 2007a; Heinze et al. 2019; Schlagberger et al. 2016), but 
this method has strong limits because Nobel prizes are awarded to extremely infrequent scientific 
achievements. It can therefore be applied to big science producers—e.g., the USA, the EU, Massachusetts 
Institute of Technology (MIT), Harvard University, University of Cambridge, etc.—but in most countries 
and institutions it is a useless procedure because there are no Nobel prizes to be counted. Although Nobel 
prizes cannot be used as indicators of research performance, however, they can be used to validate other 
indicators, which demonstrates that many bibliometric indicators do not correlate with the number of 
Nobel prizes (Rodríguez-Navarro 2011). 
Accepting that what really counts in the progress of science are the infrequent scientific breakthroughs 
that cannot be counted in most countries and institutions, the conclusion is that research indicators cannot 
be formulated by simply counting something. The alternative is to calculate the probability or expected 
frequency of the infrequent achievements that boost the progress of knowledge; it has been previously 
shown that this can be calculated from the frequency of much less cited papers (Rodríguez-Navarro and 
Brito 2019b). This is because by considering their number of citations, the rank of local papers expressed 
as a function of their global rank follows a power law (Rodríguez-Navarro and Brito 2018a). As a 
mathematical consequence, the distribution of local papers in global percentiles attending to their number 
of citations also follows a power law (Brito and Rodríguez-Navarro 2018a). This power law determines the 
ep index, which allows the probability and expected frequency of the infrequent but very highly cited 
papers that locate in low percentiles of the upper tail to be calculated (e.g., top 0.01%). 
The ep index is a derivative of the exponent of the power law that percentile frequencies obey; i.e., a 
mathematical parameter that characterizes the distribution of local papers among the global papers. It 
reveals the research efficiency or breakthrough potential (Rodríguez-Navarro and Brito 2018b), namely 
the efficiency of the system in scaling up from less cited papers to highly cited papers. For example, the 
decrease of the number of papers in the top 1% of most globally cited papers with reference to the number 
of papers in the top 10% of most globally cited papers. An ep index of 0.1 indicates that as the percentile 
decreases, the number of papers in a country or institutions decreases at the same rate as in global 
publications. Therefore, if the ep index is lower than 0.1 in a country or institution, the research 
performance of that country or institution is worse than the global average. Consequently, in countries that 
are “global scientific powerhouses” the ep index has to be notably higher than 0.1—excellent research 
systems have ep index values of around 0.2. 
The probability that a random paper from a given country or institution reaches a top percentile x is 
calculated by simply raising ep to a power, as shown by the formula (Rodríguez-Navarro and Brito 2019b): 
 
P(x) = ep (2 – lgx)           (1) 
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As a first approximation, it can be assumed that important breakthrough papers are linked to radical 
innovations and future technologies, while incremental innovations in present technologies are linked to 
less cited papers (Dewar and Dutton 1986); therefore, a meaningful research assessment should also 
provide the probability and expected frequencies of these papers. The ep index fulfills this condition 
because probabilities at all citation levels are powers of the ep index; probabilities at high citation levels— 
infrequent achievements/high powers of the ep index—correlates with the number of Nobel prizes (Brito 
and Rodríguez-Navarro 2018a) and probabilities at low citation levels—more frequent achievements/low 
powers of the ep index—correlates with peer reviews (Rodríguez-Navarro and Brito 2019a; Traag and 
Waltman 2019). 
 
5. Rationale and design of this study 
 
Assuming that, in general terms, the weak research performance of the EU has been demonstrated 
(Albarrán et al. 2010; Bauwens et al. 2011; Bonaccorsi 2007; Bonaccorsi et al. 2017a; Dosi et al. 2006; 
Herranz and Ruiz-Castillo 2013; Rodriguez-Navarro and Narin 2018; Rodríguez-Navarro and Brito 2018b), 
the first aim of this study was to characterize it in more detail. An accurate characterization would allow its 
causes to be studied, as well as avoiding the “wrong diagnosis and misguided policies” (Dosi et al. 2006, p. 
1461) that have characterized EU research for many years. For example, the EU research policy of 
increasing investments to reach 3% GDP (European Commission 2010a, 2018a) might not result in the 
expected improvement were the main causes of the weak performance not modified by higher investments. 
In fact, “the way the money is used is probably as critical as the amount of money itself” (Bauwens et al. 
2011, p. 20). 
As presented in Section 3, previous studies suggest that responsibility for the weak research 
performance in the EU lies mainly with GFIS; a study of these four countries as a single set has advantages 
in comparison to the study of independent countries, not only because the conclusions are more 
representative—GFIS represent around 50% of the EU’s population—but, more importantly, because the 
study of a set of countries allows for a larger base of research publications, making it statistically more 
robust. According to the ep index in technological and biotechnological areas, and basic medical research, 
research performance in Germany is better than in France, Italy, and Spain; however, the differences are 
small when taking a competitive country, such as Switzerland, as a reference (Brito and Rodríguez-
Navarro 2018b; Rodríguez-Navarro and Brito 2018b). GFIS are thus more similar in their weakness, as 
compared to Switzerland, than different in their degrees of weakness. 
The study of a single set of countries with weak research performances has, nonetheless, the 
inconvenience of lacking a reference of similar countries—in Europe—with competitive research 
performance. We therefore selected a reference set comprising the UK, the Netherlands, and Switzerland 
(henceforth UKNCH) for comparison in the analyses. The comparative research performances of UKNCH 
in fast evolving technologies and basic medical research vary notably (Brito and Rodríguez-Navarro 
2018b; Rodríguez-Navarro and Brito 2018b) because university specialization in Europe (Bonaccorsi et al. 
2017b) has a strong effect on small countries. Therefore, although UKNCH research performance is taken 
as a reference in this study, our results are not indicative of the research performances of the individual 
countries. 
We studied domestic papers at the ERA level—i.e., papers authored by at least one GFIS or UKNH 
researcher plus others from ERA countries external to GFIS and UKNCH, but none from non-ERA 
countries. Therefore, collaborations of ERA countries external to GFIS and UKNCH could exist in any of 
the two sets of independent papers. 
As already advanced in Section 2, another basic design of our study involves taking advantage of the 
EU funding programs, especially the ERC program, to select for different levels of excellence. The 
rationale is simple: the scientific success of a certain country or association of countries depends on a 
combination of: the ability of its researchers, their funding resources, and research environment—we use 
this term in a broad sense, including everything from stocks of knowledge to national evaluation methods 
(Sandström and van-den-Besselaar 2018). By selecting a specific type of funding some of the country 
differences are eliminated and further insights are possible. 
Statistically, citations follow a lognormal distribution (Rodríguez-Navarro and Brito 2018a; Viiu 2018; 
and references therein) where the μ and σ parameters of the lognormal function increase in parallel with 
research success. If a subpopulation in a given country is made up of the most capable researchers—e.g., in 
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an elite research university—it is certain that, ceteris paribus, the lognormal citation distribution of their 
publications will have higher μ and σ parameters than that of the total population. Because countries have 
complex research systems made up of multiple subpopulations of researchers, a low average capacity can 
be explained by (i) the low performance of all researchers due to a generally poor research environment 
and insufficient funding, and (ii) the existence of many low research performance institutions that conceal 
the high performance of a few elite institutions. 
These two possibilities can be distinguished by studying the ERC-funded GFIS and UKNCH 
publications. The ERC was created to promote excellence in science (Celis and Gago 2014; Luukkonen 
2014), and it is based on generous funding and the selection of the most excellent research projects. 
Generous funding could correct insufficient funding in a country or set of countries, but not a poor research 
environment. It is therefore likely that studying the ERC-funded subpopulations will provide information 
about the research environment in GFIS and UKNCH. 
ERC-funded GFIS research was also compared with the research of an elite institution. The ERC 
funding of research projects represents an ex ante selection that is significantly different from the selection 
of researchers in elite research institutions, whose members are mainly selected via an ex post research 
assessment improved with multiple considerations of future perspectives. The selected researchers then 
obtain generous funding. We studied the effect of these two models for selecting excellence by comparing 
MIT and ERC-funded GFIS publications. 
 
6. Analyses based on lognormal distributions 
 
Most results in this study were obtained through the use of the ep index, which is based on analysis of 
the distribution of local publications among global publications (Rodríguez-Navarro and Brito 2019b). 
Citation distributions are lognormal (Rodríguez-Navarro and Brito 2018a; Viiu 2018; and references 
therein) and local comparisons can also be performed by omitting the comparison with global publications 
through the more direct but less accurate method of comparing lognormal distributions of citations. In this 
method, once the parameters of the lognormal distributions of a country, institution, or subpopulation of 
papers have been calculated, the cumulative probability at any citation level can be calculated. In absolute 
terms, local probabilities do not have a clear meaning, but this meaning can be obtained through 
comparison with a reference or gold standard that publishes a similar number of papers. As already 
mentioned, MIT publications were used as a reference. 
The formulas of the lognormal distribution and upper cumulative distribution for a paper to receive 
more than Ca citations are the following (Aitchison and Brown 1963): 
 
 𝑝 𝐶, 𝜇,𝜎 = !!!!"  𝑒𝑥𝑝 − (!"!!!)!!!!              (2) 
 
 𝑝 Ca =  𝑝 𝐶, 𝜇,𝜎  𝑑𝐶!!a           (3)  
7. Technologies selected in this study 
 
The EC reasonably places emphasis on the importance of research for the economic future of the EU. 
For example, one of the main features of the new “Horizon Europe” research program is to “foster the 
EU’s industrial competitiveness and its innovation performance, notably supporting market-creating 
innovation via the European Innovation Council and the European Institute of Innovation and Technology” 
(European Commission 2018e). 
The research areas and topics to be investigated were selected in two independent fields, physical and 
chemical technologies (henceforth TECH) and biological technologies and basic medical research 
(henceforth BIO-MED), which are currently at the forefront of knowledge. They were selected in two 
previous studies (Brito and Rodríguez-Navarro 2018b; Rodríguez-Navarro and Brito 2018b), with a slight 
increase in the scope in the case of technology (see next section). These research areas and topics will 
probably continue being important and supporting market-creating innovations and healthcare 
advancements in the near and medium future. 
 
8. Methods 
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As described above (Section 3), the assessments of this study were based on an analysis of the 
percentile distribution of citations through the ep index, after fitting the data to a power law. For this 
purpose, we counted the number of papers from the two sets of countries and MIT that were in global top 
percentiles according to the number of citations, as described previously (Brito and Rodríguez-Navarro 
2018a; Rodríguez-Navarro and Brito 2018b). In previous cases, we counted the number of papers in six top 
percentiles from 7 to 35, but for ERC publications we added top percentiles 3 and 1, because, in some 
cases, the percentile distribution of ERC publications slightly deviates from the power law. In these cases, 
the ep index obtained from fitting the power law to the higher percentiles was higher than those obtained 
from fittings to the lower percentiles. When this occurs, to better predict the probability of breakthrough 
papers, which locates in top 0.01%, we normally fitted the power law to the lower percentiles instead of 
fitting the power law to all data points. 
This deviation of ERC publications from the characteristic power law that describes the percentile 
distribution of citations is surprising and suggests that it might be due the peculiar characteristics of ERC 
selection process (Section 9.5). This intriguing possibility deserves a specific study that is out of the scope 
of this paper. 
Bibliometric searches were performed in the Science Citation Index Expanded of the Web of Science 
Core Collection (WoS), using the “Advanced Search” feature. For TECH searches we used (TS=(ionic 
liquid* OR liquid electrolyte* OR liquid salt* OR energy transfer OR fuel cell* OR quantum dot* OR 
composite material* OR transistor* OR semiconductor OR superconductor OR graphene OR batter* OR 
solar cell* OR electronic OR metal organic framework* OR nano*) OR SU=Telecommunications)). For 
BIO-MED searches we used (SU=((biochemistry & molecular biology OR biotechnology & applied 
biotechnology OR cell biology OR microbiology) NOT (computer science OR mathematical & 
computational biology)) OR TS=((cancer OR crispr* OR microbiota OR stem cell* OR immunity OR 
inflamma*) NOT (statistics OR trial OR survey))). For ERC founded publications we used FT=(ERC OR 
(European Research Council)); for EU funded research excluding ERC and Marie Curie funded 
publications, we used FT=(((COST OR FEDER OR FP7 OR FP6 OR (European Social Fund) OR 
(European Regional Development Fund) OR (European Commission)) NOT (ERC OR (European 
Research Council) OR Marie Curie))). Although Marie Curie (MC) funding was excluded in these 
searches MC publications were not treated as ERC publications because they have a lower level of 
excellence (results not shown). 
We retrieved only “articles,” which excludes review papers, because review papers often receive more 
citations than the original articles on which they are based. Searches were performed between February 23 
and March 5, 2019. Some countries or sets of countries were analyzed on different days but each analysis 
on a different day was complete, including world and country citation distributions. Because the ERC 
program started in 2007, our citation analyses were performed for the years 2011–2014. 
To calculate the μ and σ parameters of lognormal distributions of citations of MIT and ERC-GFIS 
publications, we retrieved the number of citations of all publications and used the maximum likelihood 
method to fit the empirical data to a lognormal function.  
 
9. Results 
 
9.1. General appraisal of EU research performance 
 
Before going into more detail, we obtained a general appraisal of the research performance in the EU 
from Science & Engineering Indicators, published by the National Science Board of the National Science 
Foundation (National Science Board 2016, 2018). Among other indicators they report the proportions of 
papers within five citation-based global percentiles in 13 research areas for years 2002, 2004, 2012, y 2014. 
Although maximum differences between USA and EU research occur in topics that are at the forefront of 
technological knowledge (Bonaccorsi 2007; Rodriguez-Navarro and Narin 2018; Sachwald 2015), the 
National Science Board data enables a general appraisal of research performances in the EU and the USA. 
Table 1 records the ep index values in all these 104 cases—8 years and 13 research areas—which clearly 
indicate that while the USA is above the world average (ep ≈ 0.12) the EU is almost exactly at the world 
average (ep ≈ 0.10). Only in the case of “Other Life Sciences” was the EU slightly ahead of, or on par with, 
the USA. 
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Table 1 
Values of the ep index calculated from the data reported in the Science and Engineering Indicators. Data for years 
2002 and 2012 in 2016 report, and data for years 2004 and 2014 in 2018 report 
 USA EU 
Research field Year 
2002 2004 2012 2014 2002 2004 2012 2014 
Engineering 0.126 0.138 0.133 0.134 0.096 0.105 0.109 0.102 
Astronomy 0.127 0.119 0.125 0.132 0.102 0.109 0.109 0.107 
Chemistry 0.134 0.131 0.127 0.114 0.093 0.093 0.093 0.091 
Physics 0.128 0.134 0.145 0.143 0.102 0.099 0.113 0.116 
Geosciences 0.118 0.119 0.131 0.130 0.095 0.103 0.109 0.111 
Mathematics 0.121 0.126 0.109 0.112 0.091 0.096 0.095 0.106 
Computer sciences 0.137 0.139 0.142 0.138 0.082 0.082 0.100 0.090 
Agricultural sciences 0.129 0.118 0.127 0.128 0.100 0.106 0.118 0.112 
Biological sciences 0.119 0.119 0.129 0.132 0.095 0.100 0.113 0.111 
Medical sciences 0.127 0.126 0.132 0.135 0.096 0.100 0.117 0.118 
Other life sciences 0.103 0.102 0.108 0.102 0.104 0.104 0.112 0.111 
Psychology 0.115 0.111 0.121 0.110 0.084 0.102 0.096 0.105 
Social sciences 0.120 0.119 0.118 0.119 0.083 0.094 0.100 0.107 
         
Mean 0.123 0.123 0.127 0.125 0.094 0.100 0.106 0.107 
Science and Engineering Indicators 2016 and 2018, National Science Board, National Science Fundation, Arlington, 
VA. Appendix Tables 5-59 and 5-48, respectively. In the ep index, the higher the better. 
 
In “Engineering,” the means of the ep index values of the four evaluations is 0.13 for the USA and 0.10 
for the EU. The top 0.01% of most cited papers reasonably represents the percentile where most 
breakthrough and landmark publications concentrate (Bornmann et al. 2018; Brito and Rodríguez-Navarro 
2018a), and the probability that a random paper locates in this percentile—ep index raised to the fourth 
power, Eq. (1)—reveals the efficiency of research systems in making discoveries. The probability that a 
random paper reaches the 0.01 percentile in the field of “Engineering” is 2.9E-04 in the USA and 1.0E-04 
in the EU, 2.9 times higher in the USA than in the EU. This is a notable difference that implies that the EU 
should publish 2.9 times more papers to obtain the same number of achievements. 
The Science & Engineering Indicators reports have no data that allows a comparison of GFIS and 
UKNCH research. Therefore, we obtained a general overview of their differences by counting the number 
of universities among the top universities in the Leiden Ranking (Ranking 2019). For this purpose, we 
counted the number of GFIS and UKNCH universities among the top 25, 50 and 100 universities ordered 
by the Ptop 1% in the field of “Physical sciences and engineering,” in two time periods, 2006–2009 and 
2014–2017 (Table 2). The differences between UKNCH and GFIS were striking in the top 25, because in 
the two periods UKNCH had four and five universities while GFIS had none. In the top 50, UKNCH has 
eight and seven, and GFIS has three and zero universities in the two periods, respectively. In the top 100, 
again UKNCH performed better than GFIS. In the first period GFIS has 10 universities that decreased to 
only four in the second period. Differences between the two periods were due to the emergence of China as 
a global scientific powerhouse, which impaired the rank of GFIS universities the most, and had a lesser 
effect on UKNCH than on the USA universities. 
 
Table 2 
Number of universities among the top 25, 50 and 100 in the CWTS Leiden Ranking in periods 2006–2009 and 2014–
2017 in the research field of “Physical sciences and engineering,” Ptop 1% indicator 
Country/ 
Set 
2006–2009 2014–2017 
Top 25 Top 50 Top 100 Top 25 TOP 50 Top 100 
USA 17 28 45 11 20 31 
UKNCH 4 8 17 5 7 11 
GFIS 0 3 10 0 0 4 
China 1 3 7 7 17 35 
UKNCH: the UK, Netherlands, and Switzerland; GFIS: Germany, France, Italy, and Spain. Source 
https://www.leidenranking.com/ranking/2019/list, accessed May 22, 2019 
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9.2. EU-funded publications in TECH and BIO-MED research 
 
This study focuses on TECH and BIO-MED; the number of papers published by GFIS and UKNCH in 
BIO-MED is rather high. In BIO-MED, it represents about 17-18% of the total number of publications; in 
TECH the proportion decreases to approximately 13% and 10% in GFIS and UKNCH, respectively (Table 
3). These figures show that in addition to its economic importance, we are dealing with a paramount 
research activity in the investigated countries. The difference in the total number of papers between 
UKNCH and GFIS roughly reflects their population difference. 
 
Table 3 
Total number of publications, and number of publications in chemical and physical technologies (TECH), and 
biotechnology and basic medical research (BIO-MED) from Germany, France, Italy, and Spain (GFIS), and from UK, 
Netherlands, and Switzerland (UKNCH) 
Year GFIS UKNCH 
Total TECH BIO-MED Total TECH BIO-MED 
2011 143,017 17,801 24,994 62,048 5,606 11,171 
2014 149,224 20,080 26,828 63,066 6,250 10,884 
2018 144,404 19,806 24,453 61,590 6,533 10,030 
 
The data in Table 3 shows a situation of concern for both UKNCH and GFIS because the number of 
publications did not increase in the period from 2011 to 2018, when it is well known that several Asian 
countries were contributing to a notable increase in the number of publications and research advancements 
in these technological areas (Brito and Rodríguez-Navarro 2018b; Rodriguez-Navarro and Narin 2018; 
Rodríguez-Navarro and Brito 2018b). The consequence is that the share of global publications in TECH 
and BIO-MED have been continuously decreasing from 2011 to 2018 in both GFIS and UKNCH. 
This decrease in the share of publications is especially worrying for GFIS because the ep index values 
for TECH and BIO-MED publications were (0.06–0.07) much lower than the world average (Table 4). 
Taking these two facts together, the effect is that the research by GFIS in technological areas and basic 
medicine could eventually become of low global relevance in terms of scientific advancement. As 
described in Section 5, our next step was thus to study the reasons for this low research performance by 
analyzing the subpopulations of elite papers selected according to their funding sources. 
The subpopulation of papers selected by their EU funding in programs other than ERC and MC was 
higher in GFIS than in UKNCH in the two technologies (Table 4; 14% versus 12% in TECH, and 8.6% 
versus 5.4% in BIO-MED, for GFIS and UKNCH respectively). In GFIS the selection by this EU funding 
involved a weak increase of the ep index, a roughly 10%, with reference to that of the total number of 
papers. This indicates a practically nonexistent selection of above-average research in these programs. In 
contrast, this funding clearly increased the ep index in UKNCH, from 0.10 to 0.14, which indicates a 
notable selection of above-average research. 
 
Table 4 
Publications in TECH and BIO-MED from Germany, France, Italy, and Spain (GFIS) and from the UK, the 
Netherlands, and Switzerland (UKNCH): number and proportion of publications, and ep index by type of funding. 
Year 2014 
Country set/funding TECH publications BIO-MED publications 
Number Percent ep Number Percent ep 
GFIS       
All papers published 20080 100 0.062 26828 100 0.066 
EU funded not (ERC or MC) 2813 14.0 0.066 2305 8.6 0.075 
ERC funded 726 3.6 0.143 510 1.9 0.166 
UKNS       
All papers published 6250 100 0.104 10884 100 0.103 
EU funded not (ERC or MC) 751 12.0 0.145 592 5.4 0.144 
ERC funded 534 8.5 0.191 414 3.8 0.271 
 
The study of the ERC funded papers is more interesting because ERC funding is based on the selection 
of the highest research excellence through high quality peer review (Celis and Gago 2014; Luukkonen 
2014). The proportion of this elite subpopulation (Table 4) was considerably lower in GFIS than in 
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UKNCH—3.6% versus 8.5% and 1.9% versus 3.8% in TECH and BIO-MED, respectively—which once 
more denotes the lower research competitiveness of GFIS. Interestingly, despite the apparently more 
stringent selection by ERC funding in GFIS than in UKNCH, the ep index had lower values for ERC-GFIS 
than for ERC-UKNCH papers, 0.14 and 0.17 versus 0.19 and 0.27 in TECH and BIO-MED, and GFIS and 
UKNCH, respectively. 
This lower success of GFIS versus UKNCH in ERC-funded publications in TECH and BIO-MED is a 
general trend also seen in the number of ERC grants in all fields over the years (Fig. 1). This number 
increased continuously from 2007 to 2012, when it reached a plateau. Similarly, the number of ERC 
publications in TECH and BIO-MED increased from 2012 to 2016 and has remained almost constant since 
then (Fig. 2). Interpretation of these data needs to consider that the size of the GFIS research system is 
more than twice that of the UKNCH system (Table 3). 
 
 
9.3. Evolution of the ERC-GFIS, ERC-UKNCH, and MIT publications 
 
As already argued (Section 5), low ep index values in a given country might arise in two different 
research scenarios: publications were produced by either a homogeneous population of researchers of low 
competitiveness—most probably because of a poor research environment—or by a heterogeneous 
population of researchers, where some were highly competitive but others were less competitive. These 
two cases may be distinguished through the study of the ERC-funded publications because ERC funding 
implies a selection for excellence. For better representativeness, the study must include several years, 
because the ep index shows annual variations in the hot topics of this study. 
 
 
Figure 3 shows the ep index values for 2011–2014 for ERC-GFIS, ERC-UKNCH, and MIT publications 
in TECH and BIO-MED. In TECH there was no difference between ERC-UNKS and MIT publications, 
while ERC-GFIS publications showed lower ep index values. The ep index in ERC-UKNCH and MIT 
publications varies around 0.2, while in ERC-GFIS publications it was around 0.15; the ep index values for 
the three actors can be considered constant from 2011 to 2014. In BIO-MED, the ep index values in ERC-
UKNCH publications varies from 0.15 to 0.28, always below those of MIT, which varies from 0.23 to 0.33. 
In the case of GFIS the ep index values varies around 0.15. In both ERC-UKNCH and MIT publications, 
there was a clear increase in the ep index from 2011 to 2014, while it remained constant in the case of 
ERC-GFIS publications. Although irrelevant regarding the ep index, it is worth noting that the number of 
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Fig. 1. Number of grants from the 
European Research Council (ERC) 
awarded to Germany, France, Italy, 
and Spain (GFIS) and to the UK, the 
Netherlands, and Switzerland 
(UKNCH) from 2007 to 2017. Source: 
https://erc.europa.eu/, accessed 9 April 
2019; Proof of Concept grants were 
not included 
Fig. 2. Number of ERC publications in 
rapid evolving physical and chemical 
technologies (TECH) and in 
biotechnological and basic medical research 
(BIO-MED) from Germany, France, Italy, 
and Spain (GFIS), and from the UK, the 
Netherlands, and Switzerland (UKNCH) in 
years 2011−2018 
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ERC-funded publications was continuously increasing from 2011 to 2014 (Fig. 2) while the MIT papers 
remained constant around 550 (results not shown). 
 
 
 
9.4. Calculations based on the lognormal distributions: ERC-GFIS versus MIT publications 
 
A way of comparing the research performances of two countries or institutions is by comparing the 
probabilities of publishing very highly cited papers. These probabilities can be calculated from the ep index 
values Eq. (1) and from the their lognormal citation distributions Eq. (3). These two methods can be made 
equivalent, without any reference to the global papers, by selecting a number of citations for Eq. (3) that 
reasonably represent the highly cited tail that corresponds to the percentile used in Eq. (1). We used 1000 
citations for the papers published in 2011 and reduced the numbers in proportion to the lower citation 
window for the papers published in 2012–2014. 
Table 5 summarizes the MIT and ERC-GFIS probabilities and their ratios calculated following both 
approaches—Eq. (1) and Eq. (3). The results could not be equal because there was not an exact 
equivalence between the 0.01 percentile applying the ep index method and the number of citations 
reasonably but arbitrarily selected for the lognormal calculation. Nonetheless, results are totally consistent 
and exhibited similar annual variations; they unequivocally show that ERC-GFIS research competes poorly 
with MIT research in TECH and BIO-MED. 
 
Table 5 
Probability that a random ERC-GFIS or MIT paper is highly cited, calculated from the lognormal distribution of 
citations and from the ep index; and MIT/ERC-GFIS probability ratio. The top 0.01 percentile was fixed for the ep 
index method; for lognormal calculations, the number of citations was arbitrarily selected as described in the text  
Year Lognormal  
ERC-GFIS 
Lognormal 
MIT 
Lognormal probability ep probability 
top 0.01 percentile 
MIT/ERC-GFIS 
Prob. ratio 
μ σ μ σ Citations ERC-GFIS MIT ERC-GFIS MIT ep Lognor. 
TECH 
2011 3.458 1.196 3.420 1.339 1000 0.00195 0.00461 0.00051 0.00163 3.2 2.4 
2012 3.240 1.118 3.412 1.191 850 0.00086 0.00257 0.00031 0.00084 2.7 3.0 
2013 3.138 1.129 3.250 1.203 700 0.00126 0.00304 0.00043 0.00184 4.3 2.4 
2014 2.922 1.062 3.028 1.196 500 0.00097 0.00385 0.00017 0.00187 10.7 4.0 
BIO-MED 
2011 3.755 1.030 3.786 1.248 1000 0.00110 0.00617 0.00107 0.00300 2.8 5.6 
2012 3.398 0.934 3.592 1.212 850 0.00017 0.00463 0.00034 0.00555 16.2 27.1 
2013 3.325 1.068 3.566 1.290 700 0.00126 0.01036 0.00078 0.00516 6.6 8.3 
2014 3.081 0.954 3.491 1.262 500 0.00051 0.01543 0.00071 0.01321 18.7 30.1 
 
 
10. Discussion 
 
10.1. Wrong diagnoses and misguided policies 
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Fig. 3. Values of the e(p) index in years 2011−2014 of the ERC funded publications from Germany, France, Italy, 
and Spain (GFIS) and the UK, the Netherlands, and Switzerland (UKNCH); and publications from the 
Massachusetts Institute of Technology (MIT). Physical and chemical technologies (TECH; left panel) and 
biotechnology and basic medical research (BIO-MED; right panel). Curves are drawn to guide the eye. 
 11 
 
This was the title of the last section and the conclusion of a paper about European research that was 
written thirteen years ago (Dosi et al. 2006). There have been some changes since then, especially 
regarding basic research and the creation of the ERC, but essentially the situation has not altered. The EC 
brags about excellent research in opposition to academic studies (Section 1), but such excellence is an 
illusion based on incorrect assessments. 
As a first approach to further demonstrate the weaknesses of European research, we took advantage of 
the large amount of data provided by two successive reports of the Science & Engineering Indicators 
(National Science Board 2016, 2018). The advantage of using this data is that they have been generated by 
the USA’s National Science Board and not by EU academics, whose results have never been taken into 
consideration by the EC. The data recorded by the Science & Engineering Indicators include the 
distribution of papers in 13 research areas and five percentiles for four years across a span of 13 years from 
2002 to 2014. 
As discussed above (Section 9.1), according to the ep index values (Table 1), the advantage of the USA 
over the EU is high. Only in the case of “Other Life Sciences” was the EU slightly ahead of, or on par with, 
the USA. The top 0.01% of most cited papers reasonably represents the percentile where most 
breakthrough and landmark publications concentrate (Bornmann et al. 2018; Brito and Rodríguez-Navarro 
2018a). In “Engineering,” the probability that a random paper locates in this percentile is 2.9 times higher 
for a USA paper than for a EU paper. 
It is worth highlighting that the engineering research field mixes very different technologies and that the 
2.9 times difference is just the tip of the iceberg. In fast evolving technology topics, in the EU excluding 
the UK, the difference can be up to eight times (Rodríguez-Navarro and Brito 2018b). The question raised 
by these results is whether the EU excluding the UK is prepared to invest eight times more in research than 
the USA to obtain a similar number of scientific advancements. 
In summary, academic publications and very simple analyses (Table 1) show that the EU is not a global 
scientific powerhouse. If current research policy continues to be based on the same illusory, wrong 
diagnoses of scientific excellence that have oriented the EU research policy for more than 20 years, then 
EU research will not correct its weak position. Even worse, the EU had only two relevant competitors 20 
years ago, the USA and Japan, but China (together with other Asian countries) is currently in the 
competition and becoming even stronger than the USA and Japan. 
The EU’s sustained praise of its research excellence based on wrong diagnoses gives rise to misguided 
research policies and to a continuous failure in reaching predicted targets. For example, the objective of the 
Lisbon Strategy launched in 2000, that the EU becomes “the most competitive knowledge based economy 
in the world by 2010” (European Commission 2010b, p. 2), was an illusory dream unconnected to reality. 
As it could have been expected, this success was not achieved in 2010 and will not be achieved in 2020. 
This resounding failure should be a lesson that those responsible for the EU research policy should learn. 
 
10.2. Research in the EU is heterogeneous 
 
The EU is not a homogeneous set of countries as regards research (Bauwens et al. 2011; Leydesdorff et 
al. 2014); some countries are more efficient and some less efficient than the global average. As shown in 
previous studies (Bauwens et al. 2011; Brito and Rodríguez-Navarro 2018b; Rodríguez-Navarro and Brito 
2018b) UKNCH represent the efficient countries while GFIS represent the less efficient countries; 
according to empirical evidence, the addition to GFIS of Poland, Romania, Greece, Czech Republic, 
Portugal, Hungary, Bulgaria, Serbia, or a few other countries would increase the size of the set without 
improving the research efficiency of GFIS. A comparison of GFIS and UKNCH thus provides a reliable 
picture of the heterogeneity of EU research and of its weakness in most of the EU countries. It has to be 
taken into account for this comparison that the GFIS research system is more than twice that of UKNCH 
(Table 2). 
The reports of the USA’s National Science Board, which we used as a first approach to characterize EU 
research, do not include data that allows a comparison of GFIS and UKNCH research, but an overview of 
their differences can be obtained by counting the number of universities among the top global universities 
with the highest Ptop 1% indicators in the Leiden Ranking (Table 2). The results show unequivocally the low 
research level of GFIS with reference to UKNCH and the USA. If GFIS had a UKNCH level, the EU 
would probably be ahead of the USA in research. 
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10.3. Research in TECH and BIO-MED 
 
Although research in many different fields is important for the life of humans, the knowledge-based 
economy includes a more limited number of research fields, TECH and BIO-MED are representative 
samples of these fields. As mentioned above, the research performance in GFIS reasonably represents the 
average research performance of the whole EU. The low values of the ep index of GFIS in these specific 
fields (≈ 0.06; Table 4) therefore reveals the that the research performance of the EU in the areas that 
support the knowledge-based economy is worse than in wide scientific areas (ep index ≈ 0.1; Table 1). 
This scenario is absolutely baffling. It is startling that some of the EU’s weakest research is precisely in 
the research fields that are crucial for the economy. Many EC documents praise EU achievements in many 
different fields, such as cancer treatments, solar jet fuel, never ending batteries, exploring the universe, and 
so on (European Commission 2018d). These achievements are absolutely real; we have already noted that 
EU research is the research of a powerful economy (Section 1). The important question is therefore 
whether the number of such achievements is in tune with the size of the EU economy. Assuming that the 
USA and the EU are of similar sizes in terms of GDP, all the data indicates that the number of important 
EU achievements in technological fields is potentially six to eight times lower than it should be. 
In summary, it is true that the EU is “responsible for one-fifth of all R&D investment worldwide 
(European Commission 2018c, p. 78), and that it produces a certain number of notable achievements in 
technology and medicine (European Commission 2018d), but the number of those achievements in the EU 
is lower than in the USA and probably insufficient to maintain a competitive knowledge-based economy. 
 
10.4. Research assessments by elite samples of publications in TECH and BIO-MED 
 
To further investigate the differences between GFIS and UKNCH in TECH and BIO-MED we focused 
on an elite of research publications. 
In Section 5 we considered that there are two potential reasons for the low GFIS values of the ep index 
in TECH and BIO-MED (Table 4): (i) a generally weak performance due to a poor research environment, 
and (ii) a small, highly competitive population of researchers mixed with a large lesser competitive 
population; these two causes cannot be distinguished by studying the whole production in these research 
areas. Therefore, we focused on the elite sample of ERC publications. ERC grantees are selected through a 
rigorous peer-review process that considers both the excellence of the project and the previous scientific 
success of the applicants (Celis and Gago 2014; Luukkonen 2014); for the EC, the ERC, “in just a few 
years, has become the point of reference for excellent frontier research in Europe” (European Commission 
2017a, p. 27). Our data indicates that there are excellent ERC publications, but their frequency is not the 
same in all EU countries. The first difference we noticed between GFIS and UKNCH in the two research 
areas under study, TECH and BIO-MED, was in the proportion of ERC versus the total number of 
publications. This proportion in GFIS (3.6% in TECH and 1.9% in BIO-MED) was lower than in UKNCH 
(8.5% in TECH; 3.8% in BIO-MED), which suggested a higher success of UKNCH in obtaining ERC 
grants. 
The inference that a lower proportion of ERC publications in TECH and BIO-MED reveals less success 
in obtaining ERC grants cannot be checked in terms of grants in these research areas, because grants in 
these specific areas cannot be distinguished and counted. However, in the whole ERC program, different 
levels of success can be checked by comparing the total numbers of ERC grants. Although the annual 
number of ERC grants awarded to GFIS and UKNCH increased more than threefold in the 2007–2018 
period, the ratio between GFIS and UKNCH grants remained almost constant over this period (Fig. 1). 
Considering that the size of the GFIS research system is twice that of UKNCH (Table 3), the success of 
GFIS in terms of ERC grants is about half that of UKNCH. 
The lower success of GFIS in terms of ERC grants may be due to either a lower proportion of 
applications or a higher number of rejections. We cannot distinguish between these two possibilities with 
our data, but the former seems unlikely because in less stringent EU-funded programs GFIS is more 
successful than UKNCH. The ratio between GFIS and UKNCH publications in EU-funded publications in 
TECH and BIO-MED, excluding ERC and MC publications, is thus around 3.8 (Table 4), which is higher 
than the GFIS/UKNCH ratio considering the total number of publications (3.2 in TECH and 2.4 in BIO-
MED). In contrast, the equivalent ratio in ERC-GFIS/ERC-UKNCH publications is 1.3. In other words, in 
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the less stringent EU funding programs GFIS are more successful than UKNCH and in the stringent ERC 
funding program is just the opposite. It is unlikely, therefore, that the lower success of GFIS in the ERC 
funding program is due to less interest; the higher success of UKNCH versus GFIS in the ERC program 
probably reflects the higher research competence of UKNCH. 
Figure 3 shows the values of the ep index throughout four years, further demonstrating that the 
excellence of ERC publications is lower in GFIS than in UKNCH—the means of the ep index value in 
GFIS, 0.14 in TECH and 0.16 in BIO-MED, were lower than in UKNCH, 0.22 in both TECH and BIO-
MED. This is an important conclusion because ERC publications should be at the same level in GFIS and 
UKNCH—we assume that the selection procedure of grantees is the same for all countries. In other words, 
the excellence of grantees and projects are similar in GFIS and UKNCH, but the execution of the projects 
is less successful in GFIS than in UKNCH. We also used MIT publications as an external standard for the 
comparison of ERC publications (Fig. 3), and the superiority of MIT publications over ERC-GFIS 
publications is beyond doubt. 
Taken together, in terms of breakthrough frequencies, our results question the high level of excellence 
of the ERC-funded GFIS research. As indicated above, the probability of achieving important 
breakthroughs equals the ep index raised to the fourth power, and a similar probability can also be 
calculated from the lognormal distributions of citations by fixing a certain high level of citations (Section 
9.4). Global publications are ignored in the latter approach, which implies that the two calculations are 
independent—although they are conceptually equivalent and mathematically dependent (Rodríguez-
Navarro and Brito 2019b). Table 5 shows that both methods lead to the same conclusion, that of a limited 
research excellence of ERC-GFIS publications; the coherence of the results strongly supports that there is 
no flaw in the methods employed. 
In summary, GFIS shows lower competence than UKNCH at obtaining ERC grants and GFIS-ERC 
publications have a lower probability than UKNCH-ERC and MIT publications of reporting breakthroughs. 
 
10.5. Research environment conditions research performance 
 
Both MIT and ERC publications are elite samples from the total number of publications in TECH and 
BIO-MED, but originated from two completely different procedures for selecting researchers. MIT and all 
other elite research institution attract the brightest researchers because these institutions offer a superb 
research environment. Once in the institution, these researchers can freely apply for competitive research 
funding without any specific internal requirements. 
The process is completely different in the case of ERC funding. Any researcher from any ERA 
institution can apply. Only the past scientific performance of the applicant and the content of the project 
are considered for the selection. No GFIS university is among the top 25 in the CWTS Leiden ranking and 
there are few among the top 100 (Table 2), which implies that a certain number of ERC grantees can be in 
universities that do not provide a research environment that is at the expected ERC level. In many of these 
cases, ERC grantees will have to attend to many hours of teaching and bureaucracy and, at the same time, 
grantees and hired postdocs will be under great publish-or-perish pressure, which increases the quantity but 
not the quality of publications. In this research environment the productivity at the forefront of knowledge 
will be lower for ERC-GFIS grantees than for the MIT researchers. In our opinion this explains why ERC-
GFIS publications have a lower likelihood of reporting a scientific breakthrough than MIT publications 
(Fig. 3; Table 5). Again, the same conclusion is obtained by comparing ERC-GFIS and ERC-UKNCH 
publications, that equivalent, ERC-funded projects have lower probability of success if executed in GFIS 
rather than in UKNCH. 
The number of ERC-GFIS publications is only 2–4% of the total number of GFIS publications in 
TECH and BIO-MED (Table 4). If the ERC-GFIS researchers do not compete well at the forefront of 
knowledge after this stringent selection, it can only be because the whole research system is not 
competitive and other GFIS researchers will probably be even less competitive. This explains why the ep 
index of the publications of the whole population of GFIS researchers in TECH and BIO-MED is only 0.06 
(Table 4), well below the world average. 
 
10.6. Incremental versus radical innovations 
 
Our study is about research; questions about innovation have to be treated through specific approaches 
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(as in e.g., Archibugi and Filippetti 2011; Filippetti and Archibugi 2011). However, it is well established 
that innovation depends on scientific research (Jonkers and Sachwald 2018) and that “although a high level 
of efficiency can be achieved with incremental innovation performance, radical innovation performance is 
needed to avoid generating competence traps” (Forés and Camison 2015, p. 831). 
It is worth noting that ERC-funded research is addressed to produce breakthrough papers and that many 
of the top 0.01% of the globally most cited papers report breakthrough achievements; these achievements 
are basic for radical innovations—innovations that contain a high degree of knowledge. However, a large 
fraction of all technological progress lies in incremental innovations—innovations that contain a low 
degree of knowledge (Dewar and Dutton 1986). This type of innovation depends on external absorption 
and the internal creation of a type of research that might not be very highly cited and that is unlikely to be 
ERC funded. GFIS, and especially Germany and France, probably compete better in this type of research 
(Tijssen and Winnink 2018) than at the forefront of knowledge. This possibility, however, should not 
conceal the undesirable consequences of performing research with low ep index values. First, because a 
low ep index affects the performance of the whole research system and is not linked to any specific citation 
level, which includes the low-cited papers that support incremental innovations; and second, because 
present scientific breakthroughs at the forefront of knowledge are the bases for the technology that will be 
common in the mid-term future. Present-day low numbers of research breakthroughs will thus become 
future technological dependences. 
 
10.7. Might the weakness of EU technological research be corrected? 
 
We have already explained that the illusory dream of the EU becoming the most competitive 
knowledge-based economy in the world by 2010 was not achieved and might never be achieved. China’s 
scientific production is growing rapidly (Fu and Ho 2013; Leydesdorff et al. 2014) and might reach this 
target in the near future because China is developing a strong research system (Liu et al. 2017), especially 
in fast evolving technologies (Kostoff et al. 2007; Rodriguez-Navarro and Narin 2018). Copying China’s 
strategy might be very effective in the EU and it is worth noting that China has been developing its 
research system de novo, which is not the case for many EU countries. The EU’s problem with research is 
thus a problem of research policy. The lower success of Germany or France versus UK in Nobel prizes 
awards (Gros 2018) or number of highly cited researchers (Bauwens et al. 2011) does not have any other 
explanation. Should GFIS copy UKNCH research policies then they should achieve a similar success in 
research. 
The low levels of investment of some EU countries in research (European Commission 2010c, p. 9) 
suggest that the governments of some EU countries are not convinced about the economic benefits of 
research. This is confirmed in Spain, where the drastic cuts (Pain 2012) that are leading to the dismantling 
of the research system suggest that Spanish governments see research as a dispensable social activity 
(Rodriguez-Navarro and Narin 2018). The problem is not only investments, however, because the UK and 
the Netherlands invest less in research than Germany and France (European Commission 2010c, p. 9), but 
achieve a much higher probability that a random paper will reach the 0.01 percentile (the data is obtained 
by dividing the P’top0.01% indicator by the number of papers, see Table 5 in Rodríguez-Navarro and Brito 
2018b). 
In some countries, independently of other internal constraints, the repeatedly acclaimed and long-lasting 
notion of EU research excellence backed by the EC and the High Level Group mentioned above (Section 
1) might lead to a belief that it is not necessary to increase research. The consequences of this scenario are 
important because around 85% of EU public investments in research and innovation come from national 
funding (European Commission 2018a) and the EU “does not wish to usurp national authorities in the 
management and implementation of these activities”—the subsidiarity principle (European Parliament 
2017, p. 10). A necessary first step for the EU in order to return to being a global scientific powerhouse is 
to recognize its research weakness. In addition, the EC should warn the less competitive countries of their 
low-efficiency research and eventually penalize this lack of solidarity. Taking the EU’s Stability and 
Growth Pact (https://ec.europa.eu/eurostat/statistics-explained/index.php/Government_finance_statistics, 
accessed April 30, 2019), as a model, a minimal investment in research could be imposed on all EU 
country members. In contrast, it would be very difficult for the EC to impose a general research policy. 
The reasons for research weakness might be different in each country, because success depends on that 
several key prerequisites are fulfilled (Bornmann and Marx 2012), which implies that unsuccessful 
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research across countries can have multiple causes. This would explain why two countries that are so 
different in technological research, Germany and Spain, are similarly distant from Switzerland in terms of 
the ep index (Rodríguez-Navarro and Brito 2018b). In Germany, governments are interested in research and 
fund it generously (Federal Ministry of Education and Research 2018). In contrast, the Spanish 
government’s drastic cuts to research funding (Pain 2012) show that it considers research to be a 
dispensable activity. The answer to the question of why the German and Spanish ep index values in 
technological research are, nonetheless, not too dissimilar might shed light on the general problems of 
GFIS regarding excellence in research. 
A likely possibility is that the difficulties that GFIS researchers experience in carrying out competitive 
research might be related to their universities (Bauwens et al. 2011). In most advanced countries 
universities play a decisive role in national research and there might be a causal relationship between weak 
research and the absence of universities in top positions in the Leiden Ranking. Although this causal 
relationship has to be specifically studied, it is clear that some types of university governance might be 
determinant of low research performance (Aghion et al. 2020). For example, a high degree of cronyism 
and an institutional culture that does not favor competition, creativity, intellectual risk, and openness to the 
outside world impair research performance (Rodríguez-Navarro 2009). University governances are very 
different across countries (Paradeise et al. 2009) and general recommendations for improvements (Group 
2009) might be of little help. Each country should take care of its own university system, but the results 
should be controlled by the EC, as in the EU’s Stability and Growth Pact. If the EU genuinely wants to 
recover its past status as global scientific powerhouse and to maintain a competitive, knowledge-based 
economy in the near future, then strict measures should be taken by all EU countries regarding research. 
While it is necessary (Pavitt 2000), but not sufficient, to increase research investments, illusory 
declarations of excellence will certainly impede improvements. 
 
11. Conclusions 
 
Our study distinguishes research success between the more competitive (UKNCH) and less competitive 
(GFIS) countries. It is surprising that among advanced countries as physically close as the Netherlands, 
Switzerland, Germany, and France, it is the Netherlands and Switzerland that are highly competitive, while 
Germany and France are much less competitive at the forefront of technological knowledge. The first 
purpose of the EU research policy should be to correct the deficient research performance observed in 
GFIS and in many other EU countries. The EU would be a global scientific powerhouse if most of its 
countries were as efficient as UKNCH are. 
The finding that the probability that a random ERC publication reports a breakthrough is higher in 
UKNCH than in GFIS clearly suggests that the weakness of GFIS research is not just a problem of funding 
for research projects. Our results support that similarly ERC-funded projects are more successful if they 
are executed in UKNCH rather than in GFIS. Therefore, although an increase in investment is necessary, 
the EU will not improve its research performance by exclusively increasing investments and expanding the 
ERC program. The improvement of the observed low research performance by most of EU country 
members requires political measures. 
In this scenario, the repeated assertion that EU research is excellent operates against the solution of the 
problem. The conviction of governments that the science performed in their countries is excellent 
demotivates them from investing more in research and from making reforms that are necessary but 
unpopular. The failure of the strategic goal of the Lisbon European Council in 2000 of the EU becoming 
the most competitive knowledge-based economy by 2010 is a lesson that should be learned. 
The EU’s Stability and Growth Pact only includes financial rules, without considering that economic 
growth also depends on the generation of knowledge. The future of the EU will not be insured by the sole 
application of financial rules. 
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